Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype
NCT ID: NCT01710436
Last Updated: 2013-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
880 participants
OBSERVATIONAL
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Correlation Between Genetic Polymorphism, Platelet Activity, Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients
NCT01255267
Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
NCT02048228
Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
NCT00405717
Platelet Function Assessment for Atherothrombotic Patients
NCT00513149
Comparison Of Efficacy and Safety Between Ticagrelor and Clopidogrel In Chinese
NCT03239067
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose - Wild genotype (LW)
75mg Qd \> 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
No interventions assigned to this group
Low dose - Variant genotype (LV)
75mg Qd \> 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
No interventions assigned to this group
High dose - Wild genotype (HW)
300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
No interventions assigned to this group
High dose - Variant genotype (HV)
300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* expected dual antiplatelet therapy (DAPT) at least 6 months
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaoxing Zhang
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiovascular Institute and Fu Wai Hospital, CAMS & PUMC
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang X, Yan L, Wang D, Li Y, Han L, Tian L, Liu H, Li Y. Comparison of loading with maintenance dose of clopidogrel on platelet reactivity in Chinese with different CYP2C19 genotypes prior to percutaneous coronary intervention. Chin Med J (Engl). 2014;127(14):2571-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RDPAC2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.